Skip to Main Content

Paper Details

Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Leukemia
24
2023
ABL Myristoyl Pocket, ABL1, ASCEMBL, Asciminib, BCR, CML, CML-, MCyR, Myristoyl, asciminib, bosutinib, chronic myeloid leukemia, chronic-phase chronic myeloid leukemia, patients, tyrosine, tyrosine kinase
Author NameAffiliation
Dong Wook KimUijeongbu Eulji Medical Center
Dong Wook KimUijeongbu Eulji Medical Center
  • 1 - 2

Datasets

Release 1.2